Every Form 4 that SANUWAVE Health, Inc. (SNWV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNWV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNWV filings page.
SANUWAVE Health director Jeffrey Blizard received a grant of 5,524 stock options on June 30, 2026. The options have an exercise price of $10.0000 per share, are exercisable into 5,524 shares of common stock, and were fully vested at the grant date. Following this compensation-related award, Blizard holds 5,524 derivative securities with an expiration date of June 30, 2031, and no open-market purchases or sales were reported in this filing.
SANUWAVE Health director Ian D. Miller received a grant of stock options, giving him the right to acquire 6,215 shares of Common Stock. The options have an exercise price of $10.00 per share, were fully vested on the grant date, and expire on June 30, 2031. Following this award, he holds 6,215 derivative securities directly.
SANUWAVE Health, Inc. director Gregory Matthew Bazar received a grant of stock options as part of his compensation. He was awarded 5,524 options to buy Common Stock at an exercise price of $10.00 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds stock options for 5,524 underlying shares directly, with no shares reported as bought or sold in the market.
SANUWAVE Health director Tyler James received a new stock option grant. He was awarded options covering 5,524 shares of Common Stock at an exercise price of $10.0000 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds 5,524 derivative securities directly.
SANUWAVE Health, Inc. reported that Chief Executive Officer C. Frank Morgan received a grant of stock options covering 5,524 shares of common stock. The options have an exercise price of $10.0000 per share and expire on June 30, 2031. The filing states these options were fully vested on the grant date, and following this award he holds options for 5,524 underlying shares directly.
Opaleye Management Inc., a more than ten percent holder of SANUWAVE Health, Inc., reported open-market sales of a total of 35,581 shares of common stock. The sales occurred on April 30 and May 1 at weighted average prices of $16.1510 and $16.1105 per share, respectively, across multiple trades within disclosed price ranges. After these transactions, the filing reports 853,569 shares held through Opaleye, L.P. and 5,000 shares in a separately managed account, all owned indirectly, with Opaleye Management disclaiming beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a more than 10% owner of SANUWAVE Health, Inc., reported open-market sales of the company’s common stock over two days. On April 28, 2026, accounts it manages sold 46,288 shares at a weighted average price of $18.4674 per share, in multiple trades between $18.41 and $18.6615.
On April 29, 2026, these accounts sold an additional 24,360 shares at a weighted average price of $17.2476, in trades between $16.58 and $17.51. After the transactions, Opaleye-related vehicles held 887,650 shares through Opaleye, L.P. and 6,500 shares in a separately managed account, and Opaleye Management disclaims beneficial ownership beyond its pecuniary interest.
Opaleye-related entities reported open-market sales of SANUWAVE Health, Inc. common stock. On April 17, Opaleye, L.P. sold 11,267 shares at a weighted average price of $20.4611 per share, and a separately managed account sold 5,000 shares at the same price.
On April 21, Opaleye, L.P. sold an additional 202 shares at a weighted average price of $20.5025. Following these transactions, Opaleye, L.P. held 954,798 shares, and the managed account held 10,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
SANUWAVE Health, Inc. director Tyler James reported receiving a grant of stock options. The award covers 3,208 options, each giving the right to buy one share of common stock at an exercise price of $17.29 per share. According to the filing, these options were fully vested on the grant date and expire on March 31, 2031. Following this grant, James holds 3,208 stock options directly, with no common stock purchases or sales reported in this filing.
SANUWAVE Health, Inc. reported that Chief Executive Officer Frank C. Morgan received a grant of stock options. He was awarded options to purchase 3,208 shares of common stock at an exercise price of $17.29 per share, fully vested on the grant date. These options expire on March 31, 2031, and following this grant he holds 3,208 stock options directly.
SANUWAVE Health, Inc. director Jeffrey Blizard reported a grant of stock options as part of his compensation. On March 31, 2026, he acquired 3,208 stock options, each giving the right to buy one share of common stock at an exercise price of $17.29.
The options were fully vested at the grant date and expire on March 31, 2031. Following this grant, Blizard holds 3,208 derivative securities directly, reflecting a routine award rather than an open-market purchase or sale.
SANUWAVE Health director Gregory Matthew Bazar received a grant of stock options covering 3,208 shares of Common Stock. The options have an exercise price of $17.29 per share and were fully vested on the grant date.
The options expire on March 31, 2031, and give him the right to buy up to 3,208 shares if exercised.
SANUWAVE Health, Inc. director Ian D. Miller received a grant of stock options covering 3,609 shares of common stock. The options have an exercise price of $17.29 per share, were fully vested on the grant date, and expire on March 31, 2031. Following this compensation award, Miller holds 3,609 derivative securities directly, with no related share sales or open-market purchases reported in this filing.
SANUWAVE Health executive receives stock option grant
SANUWAVE Health, Inc. granted Exec VP of Sales David Timothy Wern a stock option for 2,500 shares of common stock on January 30, 2026. The option has an exercise price of $26.96 per share and expires on January 30, 2036.
The filing shows the full 2,500 options are held directly after the transaction. According to the footnote, these options will vest over three years in 12 equal quarterly installments starting from the grant date, tying the award to ongoing service and performance over time.
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.
The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.
SANUWAVE Health Chief Executive Officer Morgan C. Frank, who also serves as a director, reported receiving a new stock option award. On 12/31/2025, he was granted a stock option to buy 1,540 shares of common stock at an exercise price of $29.84 per share. The filing states that these options were fully vested at the grant date, meaning they are immediately exercisable, and they carry an expiration date of 12/31/2030. After this grant, Frank beneficially owns 1,540 derivative securities in the form of these stock options, held directly.
SANUWAVE Health, Inc. director Tyler James reported receiving a stock option grant. On December 31, 2025, he was awarded 1,540 stock options giving the right to buy common stock at an exercise price of $29.84 per share. These options are shown as fully vested at the grant date and expire on December 31, 2030. After this grant, James beneficially owned 1,540 derivative securities, all held directly.
SANUWAVE Health, Inc. reported an insider equity award for director Jeffrey Blizard. On 12/31/2025, he received a stock option to purchase 1,540 shares of common stock at an exercise price of $29.84 per share, expiring on 12/31/2030.
The option was fully vested on the grant date, meaning it was immediately exercisable. Following this award, Blizard beneficially owns 1,540 derivative securities related to the company’s common stock, held as a direct ownership position.
SANUWAVE Health affiliated holders reported sales of the company’s common stock by a group including JEB Partners, L.P. and related investment entities. On December 11, 2025, they sold 13,500 shares at a weighted average price of $31.2798, followed by a sale of 6,500 shares on December 12, 2025 at a weighted average price of $21.0444, both reported with transaction code “S.”
Following these transactions, 63,999 shares of SANUWAVE Health common stock were reported as indirectly beneficially owned through JEB Partners, L.P., with indirect interests attributed to Manchester Management Company, LLC, Manchester Management PR, LLC and James E. Besser. Additional lines report 2,000 shares directly owned by James E. Besser, 863,980 shares owned directly by Manchester Explorer, L.P., and 52,653 securities and warrants directly owned by Morgan C. Frank, with each party disclaiming beneficial ownership beyond their pecuniary interest.
Opaleye Management Inc. reported acquiring 1,267 shares of SANUWAVE Health, Inc. (SNWV) on 10/06/2025 at a weighted average price of $30.277 per share. After the transaction, Opaleye reports beneficial ownership of 966,267 shares through Opaleye, L.P. and an additional 15,000 shares held in a separately managed account for a total indirect position reported.
The filing clarifies the price is a weighted average from multiple trades between $29.75 and $30.50, and states that Opaleye Management Inc. disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed by James Silverman, President, dated 10/09/2025.
Jeffrey Blizard, a company director of SANUWAVE Health, Inc. (SNWV), reported the acquisition of 1,342 shares of common stock through the exercise of a stock option on 09/30/2025. The option had an exercise price of $37.48 and the underlying shares are exercisable through 09/30/2030. The filing states the options were fully vested at grant date and lists the transaction as a direct ownership change. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Ian D. Miller, a director of SANUWAVE Health, Inc. (SNWV), reported a Form 4 showing the acquisition on 09/30/2025 of 1,510 stock options with an exercise price of $37.48. The options were reported as fully vested at grant and are exercisable beginning 09/30/2025 with an expiration of 09/30/203010/02/2025. The filing lists the reporting person’s address in Eden Prairie, MN and indicates the Form was filed by one reporting person.